Transgene
ISIN: FR0005175080 | Ticker: TNG | LEI: 969500PDJW8N0FSGGK69
Country: France
Transgene is a publicly traded French biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer.
A pioneer in viral vectors engineering, we have one ambition: design innovative treatments in the fight against cancer.
Our approach uses the mechanisms of the immune response to enable the patient’s body to fight against disease.
1979
Served areaWorldwide
Headcount160
HeadquartersParc d'Innovation 400 Boulevard Gonthier d Andernach, 67405 Illkirch Graffenstaden Cedex – France
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Assets | N/A | 85,453,000.00 | 101,838,000.00 | 66,436,000.00 |
| Noncurrent Assets | N/A | 54,766,000.00 | 39,593,000.00 | 19,930,000.00 |
| Property Plant And Equipment | N/A | 13,110,000.00 | 11,295,000.00 | 11,177,000.00 |
| Intangible Assets Other Than Goodwill | N/A | N/A | 92,000.00 | 77,000.00 |
| Other Noncurrent Nonfinancial Assets | N/A | N/A | 7,434,000.00 | 7,003,000.00 |
| Other Noncurrent Assets | N/A | 7,473,000.00 | 7,434,000.00 | N/A |
| Current Assets | N/A | 30,687,000.00 | 62,245,000.00 | 46,506,000.00 |
| Current Trade Receivables | N/A | N/A | 10,133,000.00 | 2,789,000.00 |
| Other Current Financial Assets | N/A | 21,077,000.00 | 43,658,000.00 | 22,423,000.00 |
| Other Current Nonfinancial Assets | N/A | N/A | 2,543,000.00 | 2,546,000.00 |
| Cash and cash equivalents | 1,343,000.00 | 5,277,000.00 | 5,911,000.00 | 4,403,000.00 |
| Noncurrent Assets Or Disposal Groups Classified As Held For Sale | N/A | N/A | 0.00 | 14,345,000.00 |
| Other Current Assets | N/A | 2,666,000.00 | 2,543,000.00 | N/A |
| Equity And Liabilities | N/A | 85,453,000.00 | 101,838,000.00 | 66,436,000.00 |
| Equity | N/A | 50,716,000.00 | 67,209,000.00 | N/A |
| Issued Capital | N/A | 41,921,000.00 | 48,886,000.00 | 50,102,000.00 |
| Retained Earnings Profit Loss For Reporting Period | N/A | N/A | -19,536,000.00 | -32,804,000.00 |
| Retained Earnings Excluding Profit Loss For Reporting Period | N/A | N/A | -31,092,000.00 | -50,628,000.00 |
| Equity Attributable To Owners Of Parent | N/A | N/A | 67,209,000.00 | 37,841,000.00 |
| Liabilities | N/A | 34,737,000.00 | 34,629,000.00 | 28,595,000.00 |
| Noncurrent Liabilities | N/A | 21,108,000.00 | 20,040,000.00 | 15,813,000.00 |
| Noncurrent Provisions For Employee Benefits | N/A | N/A | 3,958,000.00 | 3,282,000.00 |
| Other Noncurrent Nonfinancial Liabilities | N/A | N/A | 841,000.00 | 204,000.00 |
| Other Noncurrent Liabilities | N/A | 110,000.00 | 841,000.00 | N/A |
| Longterm Borrowings | N/A | N/A | 15,241,000.00 | 12,327,000.00 |
| Current Liabilities | N/A | 13,629,000.00 | 14,589,000.00 | 12,782,000.00 |
| Current Provisions | N/A | 511,000.00 | 48,000.00 | 23,000.00 |
| Trade And Other Current Payables | N/A | N/A | 7,692,000.00 | 6,965,000.00 |
| Other Current Nonfinancial Liabilities | N/A | N/A | 5,454,000.00 | 4,602,000.00 |
| Other Current Liabilities | N/A | 6,626,000.00 | 5,454,000.00 | N/A |
| Current Borrowings And Current Portion Of Noncurrent Borrowings | N/A | N/A | 1,395,000.00 | 1,192,000.00 |
| Line item in (eur) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue | 2,981,000.00 | 9,993,000.00 | N/A |
| Revenue From Contracts With Customers | N/A | 9,993,000.00 | 3,126,000.00 |
| Other Income | 572,000.00 | 399,000.00 | 342,000.00 |
| Profit Loss From Operating Activities | -23,993,000.00 | -23,525,000.00 | -29,904,000.00 |
| Profit Loss Before Tax | -17,231,000.00 | -19,536,000.00 | -32,804,000.00 |
| Income Tax Expense Continuing Operations | 0.00 | 0.00 | 0.00 |
| Profit (loss) | -17,231,000.00 | -19,536,000.00 | -32,804,000.00 |
| Profit Loss Attributable To Owners Of Parent | -17,224,000.00 | -19,908,000.00 | N/A |
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | N/A | -17,231,000.00 | -19,536,000.00 | -32,804,000.00 |
| Adjustments For Decrease Increase In Other Operating Receivables | N/A | 717,000.00 | -242,000.00 | N/A |
| Adjustments For Increase Decrease In Trade Account Payable | N/A | -2,057,000.00 | 2,657,000.00 | -750,000.00 |
| Adjustments For Depreciation And Amortisation Expense | N/A | N/A | 2,521,000.00 | 1,686,000.00 |
| Adjustments For Provisions | N/A | 722,000.00 | -1,031,000.00 | 191,000.00 |
| Adjustments For Sharebased Payments | N/A | 1,744,000.00 | 3,002,000.00 | 2,675,000.00 |
| Other Adjustments For Noncash Items | N/A | -320,000.00 | -112,000.00 | -41,000.00 |
| Cash Flows From Used In Operating Activities | N/A | -28,742,000.00 | -25,909,000.00 | -20,303,000.00 |
| Cash Flows From Used In Investing Activities | N/A | 17,742,000.00 | -5,789,000.00 | 20,272,000.00 |
| Proceeds From Issuing Shares | N/A | 0.00 | 34,129,000.00 | 0.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 1,514,000.00 | 1,277,000.00 | 1,281,000.00 |
| Proceeds From Government Grants Classified As Financing Activities | N/A | 655,000.00 | 603,000.00 | 455,000.00 |
| Other Inflows Outflows Of Cash Classified As Financing Activities | N/A | 21,041,000.00 | -22,582,000.00 | N/A |
| Cash Flows From Used In Financing Activities | N/A | 14,941,000.00 | 32,320,000.00 | -1,477,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | -7,000.00 | 12,000.00 | 0.00 |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | N/A | 3,934,000.00 | 634,000.00 | -1,508,000.00 |
| Cash and cash equivalents | 1,343,000.00 | 5,277,000.00 | 5,911,000.00 | 4,403,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 26.05.23 | None | Other | Buy | EUR 0.00 |
FR0005175080
LEI969500PDJW8N0FSGGK69
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.